Heartcore Enterprises, INC 8-K filings

HeartCore Enterprises, Inc. announced a 39% increase in revenue for the year ended December 31, 2024, primarily driven by its Go IPO consulting services, while also reporting a net loss due to a one-time impairment charge related to its Sigmaways subsidiary.

HeartCore Enterprises, Inc. announced the formation of a Compensation Committee and a Nominating and Corporate Governance Committee after losing its status as a controlled company due to a shift in voting power.

HeartCore Enterprises, Inc. will begin delivering an investor presentation starting November 15, 2024.

HeartCore Enterprises announced a significant increase in revenue and net income for the third quarter of 2024, driven by its Go IPO consulting business and strategic shifts in its software business.

HeartCore Enterprises has successfully regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the exchange.

HeartCore Enterprises corrected a previously announced sales growth projection from 115% to 15% following the launch of its SaaS CMS platform.

HeartCore Enterprises is appealing a Nasdaq delisting notice due to non-compliance with the minimum bid price requirement, despite reporting strong preliminary Q3 2024 results.

HeartCore Enterprises has received a delisting notice from Nasdaq after failing to maintain a minimum bid price of $1.00 per share, and intends to appeal the decision.

HeartCore Enterprises reports preliminary Q3 2024 revenue and net income significantly exceeding prior year figures, driven by a successful Go IPO deal and increased software licensing.

HeartCore Enterprises held its 2024 annual meeting, where shareholders elected six directors, approved a reverse stock split, and ratified the company's independent auditors.

HeartCore Enterprises reports a significant revenue increase driven by its Go IPO client, SBC Medical Group, successfully listing on the Nasdaq, and provides strong Q3 2024 financial guidance.

HeartCore Enterprises anticipates full-year 2024 revenue of $46.6 million, according to an investor presentation released on August 19, 2024.

HeartCore Enterprises announced its second quarter 2024 financial results, highlighting growth in its software division and progress in its Go IPO business, but also a decrease in overall revenue and a net loss.

HeartCore Enterprises has declared a second dividend of $0.02 per share, totaling $417,283, reflecting the company's positive financial performance and growth.

HeartCore Enterprises announced its Q1 2024 financial results, highlighting a profitable software division but a decline in overall revenue and net income compared to the same period last year.

HeartCore Enterprises has received $9 million from a Go IPO warrant sale, but will not recognize it as revenue until the client goes public, expected in Fall 2024.

HeartCore Enterprises has received a second extension from Nasdaq to regain compliance with the minimum bid price requirement, now until October 21, 2024.

HeartCore Enterprises has signed its 14th Go IPO consulting agreement with Koei Shoji Co., Ltd., anticipating $500,000 in initial fees and a warrant for 3% of Koei Shoji's stock.

HeartCore Enterprises announced a 148% increase in revenue for 2023, driven by its enterprise software business and Go IPO consulting services, while also detailing strategic priorities for 2024.

HeartCore Enterprises has declared its first-ever dividend of $0.02 per share and anticipates record sales and gross profit in the first quarter of 2024.

HeartCore Enterprises has signed its 13th Go IPO consulting agreement with PharmaBio Corporation, expecting to generate $800,000 in fees and a warrant for 3% of PharmaBio's stock.

HeartCore Enterprises has signed a service agreement with Jyo Co., Ltd. to provide consulting services for their potential U.S. public listing, marking their 12th Go IPO contract.